RTI Health Solutions has opened a new office in Sheffield, United Kingdom.
The Sheffield office, located at Velocity House, 3 Solly Street, Sheffield, UK, marks our second office in the United Kingdom; the other is in Manchester. We also have offices in Spain and the United States.
"The Sheffield office provides us with a second United Kingdom site presence, and further expands our reach for potential collaboration with academic groups with an international reputation," said
Steve Beard, global head, health economics Europe at RTI Health Solutions. "The Yorkshire region is home to health outcomes expertise and significant post graduate programs based at both the University of York and the University of Sheffield’s School of Health and Related Research (ScHARR). Our office in Sheffield will allow for more regular face-to-face meetings and interactions with both these groups, as we work together to implement projects for our common clients.”
“We anticipate that our new office will help us in our growth strategy,” said Allen Mangel, executive vice president, RTI Health Solutions. “We strategically placed this office to allow optimal collaboration with some of the world’s leading expert outcome scientists. We also anticipate the opening of a second new European office within the next few months.”
Formed in 2000, RTI Health Solutions provides research and consulting services to help global pharmaceutical, biotechnology and medical device companies develop and commercialize their products.
RTI Health Solutions has more than 200 employees in the United States, and Europe, including experts in health economics, outcomes research, patient-reported outcomes, market access, epidemiology, biometrics, drug safety, pharmacovigilance, and preclinical and clinical development.
RTI Health Solutions combines consulting with research expertise to evaluate economic and clinical impacts of treatment, develop reimbursement dossiers, implement patient-reported outcomes and health-related quality of life studies, assess drug safety, conduct epidemiologic studies, and design and evaluate risk management programs.